MOL #24901 MOL #24901

Introduction
MOL #24901
We recently identified a novel agonist, , that potently activates the M 1 subtype but has no agonist activity on M 2 -M 5 subtypes. Using a series of chimeric receptors, we demonstrated that residues in the N-terminus/TM1 and the third outer loop (o3)/TM7 domains are required for AC-42 to elicit agonist activity at the M 1 receptor (Spalding et al, 2002) . The residues in these regions are not conserved among the muscarinic subtypes, which probably accounts for the selectivity of AC-42. Recently, was shown to act allosterically at M 1 receptors based on the observations that it did not completely displace NMS from M 1 , that it retarded the dissociation of NMS from M 1 , and that atropine antagonism of AC-42 induced functional responses yielded Schild slopes less than unity (Langmead et al, 2006) . Moreover, it has been shown that the active metabolite of the atypical antipsychotic clozapine, Ndesmethylclozapine, is a potent M 1 receptor partial agonist (Sur et al, 2003; Weiner et al, 2004; Davies et al, 2005) . We, and others (Li et al, 2005) have proposed that the M 1 agonist activity of Ndesmethylclozapine may contribute to the pro-cognitive benefits of clozapine therapy.
Ndesmethylclozapine has also been suggested to bind to M 1 receptors at a site distinct from the acetylcholine-binding site (Sur et al, 2003) .
nitrophenyl -d-galactopyranoside in phosphate-buffered saline with 5% Nonidet P-40. The resulting colorimetric reaction was measured in a spectrophotometric plate reader (Titertek, Huntsville, AL) at 420 nm. The data was fitted to the following equation using GraphPad Prism software (San Diego, CA): This article has not been copyedited and formatted. The final version may differ from this version.
Radioligand Binding Assays. Radioligand binding assays were carried out as described by Wess et al, 1991 . To determine ligand potency, washed membranes were prepared from HEK293 cells transfected with 10 micrograms plasmid DNA per 15 cm plate and stored at -80°C. Radioligand binding assays were carried out in 25 mM sodium phosphate, 5 mM magnesium chloride, 0.01% BSA (binding buffer).
Incubations were for two hours at room temperature, and reactions were stopped by rapid filtration onto GF/B filters. were: M 1 wild-type: 160 pM; W101A: 640 pM; Y106A 1,300 pM; S109A 160 pM. Expression levels for all receptors used were published by Lu and Hulme (1999) . To examine whether or not compounds could simultaneously occupy M 1 receptors, these equilibrium binding assays were repeated as described above, using CHO-M 1 cell membranes and 3 H-NMS concentrations of 0.2 nM and 2 nM.
Results
The muscarinic agonists examined in this study comprise three structural classes, orthosteric ligands such as carbachol; AC-42 and its analog AC-260584, and the antipsychotic clozapine and its active metabolite, N-desmethylclozapine (Figure 1) . The functional activity of each of these compounds was measured on wild-type rat M 1 and six receptors with mutations in TM3 using the R-SAT functional assay (Brauner-Osborne and Brann, 1996) (Table 1, Figure 2 ). The wild-type rat M 1 receptor gave a robust signal in this assay when exposed to carbachol with a maximum response typically 7-fold over basal (assigned a value of 100%, see Table 1 ). Compared with carbachol, AC-42 and Ndesmethylclozapine were each partial agonists, and clozapine displayed weak but reproducible agonist activity at M 1 as reported previously (Spalding et al, 2002 , Sur et al, 2003 , Weiner et al, 2004 , Davies et al, 2005 . AC-260584 displayed nearly full efficacy compared with carbachol, and substantially increased potency and efficacy compared to AC-42 (Figure 2A , 2B, and Table 1 ). Like AC-42, AC-260584 retains high selectivity for M 1 over the other muscarinic receptor subtypes, with greater than 50-fold selectivity versus M 2 , and no significant agonist activity at M 3 , (manuscript in preparation). As expected, all the TM3 mutants tested were severely compromised in their responses to carbachol ( Table 1 and Figure 2 ). The potency of carbachol was reduced 33-fold for W101A, 51-fold for S109A, and over 100-fold for L102A and N110A. Mutation of Y106 to alanine completely eliminated functional responses to carbachol at concentrations up to 100 uM. None of these mutated receptors showed significantly increased basal activity. The basal activities of the WT receptor and the W101A receptor were decreased slightly by atropine to ~7% and ~6% of their maximal responses to carbachol, respectively, and no significant responses were seen of any other mutant to atropine (data not shown). In contrast to the results observed with carbachol, responses to AC-42, AC-260584, clozapine and Ndesmethylclozapine were maintained at many of the mutant receptors, and greatly increased at some.
The most striking differences observed were at the W101A mutant ( Figure 2C ) where 50-fold and 33-fold increases were seen in the potencies of AC-42 and AC-260584, respectively, whereas this same mutation caused a greater than 20-fold decrease in the potency of carbachol (see Figure 2C , Table MOL #24901 1). The maximum response to AC-42 was also greatly increased at W101A, to over twice that observed at the wild-type receptor. Similarly, the maximum response to clozapine was increased almost 5-fold over that observed at the wild-type receptor, to a level comparable to carbachol ( Figure 2D) . In contrast to AC-42 and AC-260584, the potencies of clozapine and N-desmethylclozapine were not changed significantly.
Striking differences in the effects of mutations on carbachol and the other tested ligands were also seen on the Y106A and S109A mutants ( Figure 2G -2J, and Table 1 ). On Y106A, the maximum responses of N-desmethylclozapine and clozapine were increased 1.4 fold and over 7-fold respectively, compared to their responses at the wild-type receptor, whereas no response to carbachol could be detected. Small, but clear functional responses to AC-42 were observed, and robust functional responses to AC-260584 were observed at Y106A receptors. On S109A, the potencies of AC-42, AC-260584 and N-desmethylclozapine were hardly affected, while the potency of carbachol was reduced over 50-fold.
The maximal response to clozapine on S109A was not increased as it was at several of the other mutant receptors.
The L102 and N110 mutations caused significant impairment to responses induced by each of the tested ligands, but even here there were some apparent differences between carbachol and the other ligands (see Figure 2E , 2F, 2K, 2L and Table 1 ). For example, the maximum response to clozapine was increased over 2-fold on both L102A and N110A compared with wild-type receptor, whereas the maximal response to carbachol was reduced at these mutants compared with wild-type. In general, the potencies for all ligands were significantly reduced on L102A and N110A, though more for carbachol (>100 fold in each case) and less for the other ligands (typically ~30-fold in most cases).
To confirm the differential effects of these mutations upon ligand activity, we tested several of the most interesting ligand-receptor combinations in conventional phosphatidyl inositol (PI) hydrolysis assays. The potencies of carbachol, AC-260584, and N-desmethylclozapine at wild-type M 1 were very similar to that observed in RSAT ( Table 2 and Figure 3 ). AC-260584 displayed full activity relative to carbachol, N-desmethylclozapine was a partial agonist, and clozapine displayed minimal responses.
On W101A, we again observed that the potency of AC-260584, and the maximal response to clozapine were each strongly increased, while the potency of carbachol was dramatically decreased (Table 2 and Figure 3B ). On Y106A, the maximal response to clozapine was equal to Ndemethylclozapine and greater than AC-260584, and carbachol was totally inactive ( Figure 3C ). On S109A, the potency of carbachol was reduced over 50-fold, while the potencies of AC-260584 and Ndesmethylclozapine were unaffected ( Figure 3D ). AC-42 displayed qualitatively similar activities as AC-260584 on wild-type M 1 and these mutant receptors (data not shown). These results are highly consistent with the RSAT results.
To assess the effect of these mutations on receptor affinity, radioligand binding studies were carried out using the antagonist radioligand 3 H-N-methyl scopolamine ( 3 H-NMS) (see Table 3 ). The binding affinity of carbachol was significantly reduced on Y106A and S109A, though it was unchanged on W101A. Similarly, the binding affinities of the orthosteric antagonists NMS and atropine were strongly reduced at Y106A. In contrast, the affinities of AC-42, AC-260584, clozapine and Ndesmethylclozapine were only slightly affected on Y106A and S109A, and the affinities of AC-42 and AC-260584 were greatly increased at W101A.
To directly examine if N-desmethylclozapine, clozapine, AC-42 and AC-260584 act allosterically at M 1 receptors, 3 H-NMS-inhibition binding studies were performed using increased amounts of 3 H-NMS (Figure 4) . N-desmethylclozapine, clozapine, and AC-260584 were each able to completely displace 3 H-NMS, with AC-260584 requiring significantly higher concentrations than either N-desmethylclozapine or clozapine to achieve this. In contrast, AC-42 was unable to completely displace 3 H-NMS up to concentrations of 300 uM. We cannot rule out the possibility that AC-42 would completely displace 3 H-NMS at higher concentrations than 300 uM, however the compound was not soluble above 300 uM. As expected, gallamine only partially displaced 3 H-NMS, and this effect became much more pronounced as the concentration of 3 H-NMS was increased.
To Mutations to Y106 and S109 also had strikingly different effects on these ligands. M 1 -Y106A was not activated by carbachol, and its affinity for carbachol was reduced over 40-fold. In contrast, M 1 -Y106A retained the ability to be activated by AC-42 and AC-260584. Similarly, on M 1 -S109A, the potencies of AC-42 and AC-260584 were unchanged, and their maximal responses were increased, while the potency of carbachol for M 1 -S109A was decreased 50-fold in functional assays and 9-fold in radioligand binding, Mutations such as W101A that induce large potency increases are rare; frequently they are caused by increases in constitutive activity , 1998 , Burstein et al, 1998 , Lu and Hulme, 1999 as would be predicted by increasing J, the isomerization constant defining interconversion of receptors between active and inactive conformations (Samama et al 1993) . This is unlikely in this case, because the constitutive activity of the mutant and wild-type receptors were similar (see Results above), thus their J values are likely to be similar, and the receptors were expressed at similar levels (Lu and Hulme, 1999). We therefore suggest that the W101A mutation may directly strengthen interactions between AC-42 and AC-260584, and the M 1 receptor. Possibly steric constraints are removed upon replacement of a large tryptophan residue with a smaller alanine residue at this position, allowing AC-42
and AC-260584 to bind more tightly to the receptor. This strengthened interaction could involve other residues in TM3 or residues elsewhere in the receptor that are revealed by a change in receptor conformation.
According to modern models of receptor activation (Samama et al, 1993; Spalding et al, 1997; Christopoulos and Kenakin, 2002) , agonists preferentially bind to active receptor conformations; inverse agonists preferentially bind to inactive receptor conformations, and neutral antagonists have equal affinity for active and inactive receptor conformations. Therefore, clozapine is likely to bind the inactive and active conformations of M 1 with similar affinity since it is an extremely weak partial agonist at the wildtype M 1 receptor. The large increase in maximal responses to clozapine caused by most mutations in This article has not been copyedited and formatted. The final version may differ from this version. TM3 is believed to form an alpha-helix based on mutagenesis and affinity labeling data (Lu and Hulme 1999, Javitch et al, 1995; Spalding et al, 1998) and by inference from the 3D structure of rhodopsin (Palzewski et al, 2000 , Hulme et al, 2003 . To approximate their positions in the 3D structure of the M 1 receptor, the residues tested in this study were mapped onto a helical net (Figure 6 ). W101 is predicted to lie one turn above D105, Y106 is adjacent to D105, and S109 is predicted to lie one turn below D105. As described above, the side-chains of Y106 and S109 are essential for carbachol activity, suggesting that carbachol makes interactions well into the transmembrane domain of the receptor. In contrast, AC-42, AC-260584, and N-desmethylclozapine were substantially less affected by these mutations, and the activity of clozapine was dramatically increased on M 1 -Y106A, suggesting that these ligands bind closer to the extracellular space. This is consistent with data showing that carbachol, but not AC-42 or N-desmethylclozapine activity is strongly impaired, and clozapine activity is greatly increased This article has not been copyedited and formatted. The final version may differ from this version.
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by mutations of tyrosine 381 and asparagine 382 in TM6 (Spalding et al, 2002 , Sur et al, 2003 , which are also believed to lie well into the transmembrane domain. The strong potentiating effect of W101A on AC-42 and AC-260584 activity could be explained as an allosteric effect propagated to an AC-42 binding site located elsewhere, however it is more likely that AC-42 and AC-260584 interact with the extracellular regions of TM3. This is consistent with the observation that AC-42 agonist activity is dependant on M 1 sequence in the extracellular parts of the receptor such as the N-terminus and the third extracellular loop (Spalding et al, 2002) .
The strikingly different effects of these mutations on orthosteric ligands like carbachol, structural analogs of AC-42, and structural analogs of N-desmethylclozapine suggest that M 1 receptors can be activated in at least three different ways. AC-42 and AC-260584 display clear allosteric properties (Langmead et al, 2006 ; this paper), whereas we were unable to demonstrate that N-desmethylclozapine and clozapine bind allosterically, i.e. through a non-overlapping (with respect to carbachol) site. AC-42
and AC-260584 exhibit high functional selectivity for M 1 over the other muscarinic subtypes (Spalding et al, 2002 and see above), possibly because these ligands act through non-conserved amino acid residues, consistent with an allosteric mechanism of action. In contrast, N-desmethylclozapine and clozapine are substantially less selective for M 1 over the other muscarinic subtypes (Weiner et al, 2004; Davies et al, 2005) , possibly reflecting interactions more similar to those utilized by orthosteric (and non-selective) ligands like carbachol. We conclude that although N-desmethylclozapine and clozapine contact different residues than carbachol to activate M 1 , they may occupy a substantially overlapping space with carbachol, whereas AC-42 and AC-260584 appear to occupy separable spaces.
These observations demonstrate that GPCRs do not have a single agonist-binding site, where a ligand must bind to activate the receptor. Instead, receptors appear to spontaneously adopt active conformations, and ligands that stabilize one of these active conformations will act as agonists, irrespective of the site where they bind the receptor.
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